Advertisement

Drug Safety

pp 1–16 | Cite as

Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis

  • Babak Soleimani
  • Katy Murray
  • David HuntEmail author
Review Article

Abstract

Biologic immunotherapies have transformed the treatment landscape of multiple sclerosis. Such therapies include recombinant proteins (interferon beta), as well as monoclonal antibodies (natalizumab, alemtuzumab, daclizumab, rituximab and ocrelizumab). Monoclonal antibodies show particular efficacy in the treatment of the inflammatory phase of multiple sclerosis. However, the immunological perturbations caused by biologic therapies are associated with significant immunological adverse reactions. These include development of neutralising immunogenicity, secondary immunodeficiency and secondary autoimmunity. These complications can affect the balance of risks and benefits of biologic agents, and 2018 saw the withdrawal from the market of daclizumab, an anti-CD25 monoclonal antibody, due to concerns about the development of severe, unpredictable autoimmunity. Here we review established and emerging risks associated with multiple sclerosis biologic agents, with an emphasis on their immunological adverse effects. We also discuss the specific challenges that multiple sclerosis biologics pose to drug safety systems, and the potential for improvements in safety frameworks.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to assist in the preparation of this review.

Conflicts of Interest

Katy Murray has received financial support from Merck Serono, Biogen, Genzyme Sanofi, Roche and Novartis pharmaceuticals for scientific meeting attendance and consultation fees. David Hunt and Babak Soleimani have no conflicts of interest relevant to this review.

References

  1. 1.
    Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169–80.  https://doi.org/10.1056/NEJMra1401483.PubMedCrossRefGoogle Scholar
  2. 2.
    Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.  https://doi.org/10.1016/S0140-6736(08)61620-7.PubMedCrossRefGoogle Scholar
  3. 3.
    Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.PubMedCrossRefGoogle Scholar
  4. 4.
    Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5(11):932–6.  https://doi.org/10.1016/S1474-4422(06)70581-6.PubMedCrossRefGoogle Scholar
  5. 5.
    Casadevall N, Flossmann O, Hunt D. Evolution of biological agents: how established drugs can become less safe. BMJ. 2017;357:j1707.  https://doi.org/10.1136/bmj.j1707.PubMedCrossRefGoogle Scholar
  6. 6.
    Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004;22(11):1383–91.  https://doi.org/10.1038/nbt1030.PubMedCrossRefGoogle Scholar
  7. 7.
    Compston A. The modern management of multiple sclerosis. Br J Hosp Med. 1986;36(3):200-1, 204-8.Google Scholar
  8. 8.
    Daclizumab withdrawn from the market worldwide. Drug Ther Bull. 2018;56(4):38.  https://doi.org/10.1136/dtb.2018.4.0604.CrossRefGoogle Scholar
  9. 9.
    Lancet The. End of the road for daclizumab in multiple sclerosis. Lancet. 2018;391(10125):1000.  https://doi.org/10.1016/S0140-6736(18)30565-8.CrossRefGoogle Scholar
  10. 10.
    Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–34.  https://doi.org/10.1056/NEJMoa1601277.PubMedCrossRefGoogle Scholar
  11. 11.
    Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779–87.  https://doi.org/10.1016/S0140-6736(11)61649-8.PubMedCrossRefGoogle Scholar
  12. 12.
    CAMMS223 Trial Investigators, Coles AJ, Compston DA et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–801.  https://doi.org/10.1056/NEJMoa0802670.
  13. 13.
    Kalincik T, Brown JWL, Robertson N, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017;16(4):271–81.  https://doi.org/10.1016/S1474-4422(17)30007-8.PubMedCrossRefGoogle Scholar
  14. 14.
    Castro-Borrero W, Graves D, Frohman TC, et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2012;5(4):205–20.  https://doi.org/10.1177/1756285612450936.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88.  https://doi.org/10.1056/NEJMoa0706383.PubMedCrossRefGoogle Scholar
  16. 16.
    Granqvist M, Boremalm M, Poorghobad A, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75(3):320–7.  https://doi.org/10.1001/jamaneurol.2017.4011.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273–9.  https://doi.org/10.1136/practneurol-2015-001139.PubMedCrossRefGoogle Scholar
  18. 18.
    Hartung HP, Aktas O. Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurol. 2011;10(4):293–5.  https://doi.org/10.1016/S1474-4422(11)70043-6.PubMedCrossRefGoogle Scholar
  19. 19.
    Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469–75.  https://doi.org/10.1056/NEJMoa011931.PubMedCrossRefGoogle Scholar
  20. 20.
    Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375–81.  https://doi.org/10.1056/NEJMoa051847.PubMedCrossRefGoogle Scholar
  21. 21.
    Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354(9):924–33.  https://doi.org/10.1056/NEJMoa054693.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118(24):6299–305.  https://doi.org/10.1182/blood-2011-08-371138.PubMedCrossRefGoogle Scholar
  23. 23.
    Meyer D, Coles A, Oyuela P, et al. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2013;2(1):60–3.  https://doi.org/10.1016/j.msard.2012.07.002.PubMedCrossRefGoogle Scholar
  24. 24.
    Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498–504.Google Scholar
  25. 25.
    Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European study group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352(9139):1491–7.Google Scholar
  26. 26.
    Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258–67.Google Scholar
  27. 27.
    McGlasson S, Jury A, Jackson A, et al. Type I interferon dysregulation and neurological disease. Nat Rev Neurol. 2015;11(9):515–23.  https://doi.org/10.1038/nrneurol.2015.143.PubMedCrossRefGoogle Scholar
  28. 28.
    Knobler RL, Panitch HS, Braheny SL, et al. Clinical trial of natural alpha interferon in multiple sclerosis. Ann N Y Acad Sci. 1984;436:382–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Knobler RL, Panitch HS, Braheny SL, et al. Systemic alpha-interferon therapy of multiple sclerosis. Neurology. 1984;34(10):1273–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Verdun E, Isoardo G, Oggero A, et al. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases? J Interferon Cytokine Res. 2002;22(2):245–55.  https://doi.org/10.1089/107999002753536220.PubMedCrossRefGoogle Scholar
  32. 32.
    Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ. 2009;339:b4677.  https://doi.org/10.1136/bmj.b4677.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Palace J, Duddy M, Bregenzer T, et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol. 2015;14(5):497–505.  https://doi.org/10.1016/S1474-4422(15)00018-6.PubMedCrossRefGoogle Scholar
  34. 34.
    Crow MK. Autoimmunity: interferon alpha or beta: which is the culprit in autoimmune disease? Nat Rev Rheumatol. 2016;12(8):439–40.  https://doi.org/10.1038/nrrheum.2016.117.PubMedCrossRefGoogle Scholar
  35. 35.
    McGlasson S, Hunt D. Neuroinflammation: synapses pruned in lupus. Nature. 2017;546(7659):482–3.  https://doi.org/10.1038/nature23087.PubMedCrossRefGoogle Scholar
  36. 36.
    Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362(9391):1184–91.  https://doi.org/10.1016/S0140-6736(03)14541-2.PubMedCrossRefGoogle Scholar
  37. 37.
    Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology. 2009;73(5):372–7.  https://doi.org/10.1212/WNL.0b013e3181b04c98.PubMedCrossRefGoogle Scholar
  38. 38.
    Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9(7):740–50.  https://doi.org/10.1016/S1474-4422(10)70103-4.PubMedCrossRefGoogle Scholar
  39. 39.
    Farrell RA, Giovannoni G. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult Scler. 2007;13:567–77.PubMedCrossRefGoogle Scholar
  40. 40.
    Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf. 2011;2(3):113–28.  https://doi.org/10.1177/2042098611406318.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Burdick LM, Somani N, Somani AK. Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf. 2009;8(4):459–72.  https://doi.org/10.1517/14740330903066726.PubMedCrossRefGoogle Scholar
  42. 42.
    Durelli L, Ferrero B, Oggero A, et al. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci. 1999;162(1):74–83.PubMedCrossRefGoogle Scholar
  43. 43.
    Durelli L, Ferrero B, Oggero A, et al. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology. 2001;57(8):1363–70.PubMedCrossRefGoogle Scholar
  44. 44.
    Durelli L, Ferrero B, Oggero A, et al. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab. 2001;86(8):3525–32.  https://doi.org/10.1210/jcem.86.8.7721.PubMedCrossRefGoogle Scholar
  45. 45.
    Monzani F, Caraccio N, Dardano A, et al. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med. 2004;3(4):199–210.  https://doi.org/10.1007/s10238-004-0026-3.PubMedCrossRefGoogle Scholar
  46. 46.
    LiverTox. Interferon Beta-1A/1B. In: LiverTox. National Institutes of Health, U.S. Department of Health & Human Services. https://livertox.nlm.nih.gov/Interferon.htm. Accessed 27 Nov 2018.
  47. 47.
    Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology. 2004;62(4):628–31.PubMedCrossRefGoogle Scholar
  48. 48.
    Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf. 2003;26(11):815–27.  https://doi.org/10.2165/00002018-200326110-00006.PubMedCrossRefGoogle Scholar
  49. 49.
    Antonazzo IC, Poluzzi E, Forcesi E et al. Liver injury with drugs used for multiple sclerosis: a contemporary analysis of the FDA adverse event reporting system. Mult Scler. 2018:1352458518799598.  https://doi.org/10.1177/1352458518799598.
  50. 50.
    Villamil A, Mullen E, Casciato P, et al. Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature. Ann Hepatol. 2015;14(2):273–80.PubMedGoogle Scholar
  51. 51.
    Kolb-Maurer A, Goebeler M, Maurer M. Cutaneous adverse events associated with interferon-beta treatment of multiple sclerosis. Int J Mol Sci. 2015;16(7):14951–60.  https://doi.org/10.3390/ijms160714951.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Nikfar S, Rahimi R, Abdollahi M. A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type. Clin Ther. 2010;32(11):1871–88.  https://doi.org/10.1016/j.clinthera.2010.10.006.PubMedCrossRefGoogle Scholar
  53. 53.
    de Jong HJI, Kingwell E, Shirani A, et al. Evaluating the safety of beta-interferons in MS: a series of nested case–control studies. Neurology. 2017;88(24):2310–20.  https://doi.org/10.1212/WNL.0000000000004037.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(19):1847–8.  https://doi.org/10.1056/NEJMc1410951.PubMedCrossRefGoogle Scholar
  55. 55.
    Kavanagh D, McGlasson S, Jury A, et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood. 2016;128(24):2824–33.  https://doi.org/10.1182/blood-2016-05-715987.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Ben-Amor AF, Trochanov A, Fischer TZ. Cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome reports with subcutaneous interferon beta-1a. Adv Ther. 2015;32(5):445–54.  https://doi.org/10.1007/s12325-015-0212-6.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Hunt D, Kavanagh D, Drummond I, et al. Thrombotic microangiopathy associated with interferon beta. N Engl J Med. 2014;370(13):1270–1.  https://doi.org/10.1056/NEJMc1316118.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Kumasaka R, Nakamura N, Shirato K, et al. Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis. Clin Exp Nephrol. 2006;10(3):222–5.  https://doi.org/10.1007/s10157-006-0424-9.PubMedCrossRefGoogle Scholar
  59. 59.
    Tola MR, Caniatti LM, Gragnaniello D, et al. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a. J Neurol. 2003;250(6):768–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Ozturk M, Basoglu F, Yilmaz M, et al. Interferon beta associated nephropathy in a multiple sclerosis patient: a case and review. Mult Scler Relat Disord. 2016;9:50–3.  https://doi.org/10.1016/j.msard.2016.06.012.PubMedCrossRefGoogle Scholar
  61. 61.
    Yuste C, Rapalai M, Pritchard BA, et al. Nephrotic-range proteinuria on interferon-beta treatment: immune-induced glomerulonephritis or other pathway? Clin Kidney J. 2014;7(2):190–3.  https://doi.org/10.1093/ckj/sfu016.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13(7):657–65.  https://doi.org/10.1016/S1474-4422(14)70068-7.PubMedCrossRefGoogle Scholar
  63. 63.
    Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.  https://doi.org/10.1056/NEJMoa044397.PubMedCrossRefGoogle Scholar
  64. 64.
    Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–23.  https://doi.org/10.1056/NEJMoa044396.PubMedCrossRefGoogle Scholar
  65. 65.
    Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15–23.  https://doi.org/10.1056/NEJMoa020696.PubMedCrossRefGoogle Scholar
  66. 66.
    Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2013;19(5):593–600.  https://doi.org/10.1177/1352458512460604.PubMedCrossRefGoogle Scholar
  67. 67.
    Oliver-Martos B, Orpez-Zafra T, Urbaneja P, et al. Early development of anti-natalizumab antibodies in MS patients. J Neurol. 2013;260(9):2343–7.  https://doi.org/10.1007/s00415-013-6991-2.PubMedCrossRefGoogle Scholar
  68. 68.
    Svenningsson A, Dring AM, Fogdell-Hahn A, et al. Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies. Neurology. 2013;80(10):965–7.  https://doi.org/10.1212/WNL.0b013e3182840be3.PubMedCrossRefGoogle Scholar
  69. 69.
    Antezana A, Sigal S, Herbert J, et al. Natalizumab-induced hepatic injury: a case report and review of literature. Mult Scler Relat Disord. 2015;4(6):495–8.  https://doi.org/10.1016/j.msard.2015.08.008.PubMedCrossRefGoogle Scholar
  70. 70.
    Clerico M, Artusi CA, Di Liberto A, et al. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. Expert Opin Drug Saf. 2017;16(8):963–72.  https://doi.org/10.1080/14740338.2017.1346082.PubMedCrossRefGoogle Scholar
  71. 71.
    Parisinos CA, Lees CW, Wallace WA, et al. Sarcoidosis complicating treatment with natalizumab for Crohn’s disease. Thorax. 2011;66(12):1109–10.  https://doi.org/10.1136/thx.2010.155762.PubMedCrossRefGoogle Scholar
  72. 72.
    Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295–303.  https://doi.org/10.1002/ana.22128.PubMedCrossRefGoogle Scholar
  73. 73.
    Rudick RA, O’Connor PW, Polman CH, et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol. 2010;68(3):304–10.  https://doi.org/10.1002/ana.22107.PubMedCrossRefGoogle Scholar
  74. 74.
    Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–80.  https://doi.org/10.1056/NEJMoa1107829.PubMedCrossRefGoogle Scholar
  75. 75.
    Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol. 2012;12(1):25–35.  https://doi.org/10.1136/practneurol-2011-000092.PubMedCrossRefGoogle Scholar
  76. 76.
    Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925–33.  https://doi.org/10.1016/S1474-4422(17)30282-X.PubMedCrossRefGoogle Scholar
  77. 77.
    Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol. 2018;17(5):467–80.  https://doi.org/10.1016/S1474-4422(18)30040-1.PubMedCrossRefGoogle Scholar
  78. 78.
    Schwab N, Schneider-Hohendorf T, Melzer N, et al. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology. 2017;88(12):1197–205.  https://doi.org/10.1212/WNL.0000000000003739.PubMedCrossRefGoogle Scholar
  79. 79.
    Mowry EM, McArthur JC. PML in natalizumab-treated multiple sclerosis: modeling errors and risk miscalculations. Neurology. 2017;88(12):1110–1.  https://doi.org/10.1212/WNL.0000000000003749.PubMedCrossRefGoogle Scholar
  80. 80.
    O’Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858–65.  https://doi.org/10.1212/WNL.0b013e31821e7c8a.PubMedCrossRefGoogle Scholar
  81. 81.
    Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011;68(2):186–91.  https://doi.org/10.1001/archneurol.2010.257.PubMedCrossRefGoogle Scholar
  82. 82.
    Larochelle C, Metz I, Lecuyer MA, et al. Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal. Mult Scler. 2017;23(1):72–81.  https://doi.org/10.1177/1352458516641775.PubMedCrossRefGoogle Scholar
  83. 83.
    Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79(6):950–8.  https://doi.org/10.1002/ana.24651.PubMedCrossRefGoogle Scholar
  84. 84.
    Clerico M, Artusi CA, Di Liberto A, et al. Natalizumab in multiple sclerosis: long-term management. Int J Mol Sci. 2017;18(5):940.  https://doi.org/10.3390/ijms18050940.PubMedCentralCrossRefGoogle Scholar
  85. 85.
    Ryerson L, Foley J, Chang I et al. Natalizumab extended interval dosing is associated with a reduction in progressive multifocal leukoencephalopathy risk in the TOUCH® Registry. In: ACTRIMS 2018 Forum. 2018. https://actrims.confex.com/actrims/2018/meetingapp.cgi/Paper/3102. Accessed 7 Jan 2019.
  86. 86.
    Fine AJ, Sorbello A, Kortepeter C, et al. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol. 2014;75(1):108–15.  https://doi.org/10.1002/ana.24051.PubMedCrossRefGoogle Scholar
  87. 87.
    Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) Project. Lancet Oncol. 2009;10(8):816–24.  https://doi.org/10.1016/S1470-2045(09)70161-5.PubMedCrossRefGoogle Scholar
  88. 88.
    Hoepner R, Kolb EM, Dahlhaus S, et al. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2017;23(6):830–5.  https://doi.org/10.1177/1352458516667241.PubMedCrossRefGoogle Scholar
  89. 89.
    Dong-Si T, Gheuens S, Gangadharan A, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol. 2015;21(6):637–44.  https://doi.org/10.1007/s13365-015-0316-4.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009;361(11):1081–7.  https://doi.org/10.1056/NEJMoa0810316.PubMedCrossRefGoogle Scholar
  91. 91.
    Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72(5):779–87.  https://doi.org/10.1002/ana.23676.PubMedCrossRefGoogle Scholar
  92. 92.
    Linda H, von Heijne A. Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol. 2013;4:11.  https://doi.org/10.3389/fneur.2013.00011.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Landi D, De Rossi N, Zagaglia S, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017;88(12):1144–52.  https://doi.org/10.1212/WNL.0000000000003740.PubMedCrossRefGoogle Scholar
  94. 94.
    Scarpazza C, Prosperini L, De Rossi N, et al. To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. Ann Neurol. 2017;82(5):697–705.  https://doi.org/10.1002/ana.25070.PubMedCrossRefGoogle Scholar
  95. 95.
    Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391–403.  https://doi.org/10.1212/01.wnl.0000277457.17420.b5.PubMedCrossRefGoogle Scholar
  96. 96.
    Camacho-Halili M, George R, Gottesman M, et al. An approach to natalizumab hypersensitivity: a case series of induction of tolerance. Mult Scler. 2011;17(2):250–3.  https://doi.org/10.1177/1352458510388966.PubMedCrossRefGoogle Scholar
  97. 97.
    Hellwig K, Schimrigk S, Fischer M, et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol. 2008;65(5):656–8.  https://doi.org/10.1001/archneur.65.5.656.PubMedCrossRefGoogle Scholar
  98. 98.
    Krumbholz MPH, Gold R, et al. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol. 2007;64(9):1331–3.PubMedCrossRefGoogle Scholar
  99. 99.
    Fine AJ, Sorbello A, Kortepeter C, et al. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis. 2013;57(6):849–52.  https://doi.org/10.1093/cid/cit376.PubMedCrossRefGoogle Scholar
  100. 100.
    Na A, Hall N, Kavar B, et al. Central nervous system lymphoma associated with natalizumab. J Clin Neurosci. 2014;21(6):1068–70.  https://doi.org/10.1016/j.jocn.2013.10.018.PubMedCrossRefGoogle Scholar
  101. 101.
    Dahdaleh D, Altmann DM, Malik O, et al. Breathlessness, night sweats, and weight loss on natalizumab. Lancet. 2012;380(9843):726–7.  https://doi.org/10.1016/S0140-6736(12)61401-9.PubMedCrossRefGoogle Scholar
  102. 102.
    Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult Scler. 2009;15(12):1532–3.  https://doi.org/10.1177/1352458509347154.PubMedCrossRefGoogle Scholar
  103. 103.
    Castela E, Lebrun-Frenay C, Laffon M, et al. Evolution of nevi during treatment with natalizumab: a prospective follow-up of patients treated with natalizumab for multiple sclerosis. Archives of Dermatology. 2011;147(1):72–6.  https://doi.org/10.1001/archdermatol.2010.243.PubMedCrossRefGoogle Scholar
  104. 104.
    Avasarala J. It’s time for combination therapies: in multiple sclerosis. Innov Clin Neurosci. 2017;14(5–6):28–30.PubMedPubMedCentralGoogle Scholar
  105. 105.
    Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010;9(3):299–308.PubMedCrossRefGoogle Scholar
  106. 106.
    Waldmann H, Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci. 2005;360(1461):1707–11.  https://doi.org/10.1098/rstb.2005.1702.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet. 1988;2(8625):1394–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20):1909–19.  https://doi.org/10.1056/NEJMoa1009546.PubMedCrossRefGoogle Scholar
  109. 109.
    Mathieson PW, Cobbold SP, Hale G, et al. Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med. 1990;323(4):250–4.  https://doi.org/10.1056/NEJM199007263230407.PubMedCrossRefGoogle Scholar
  110. 110.
    Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–28.  https://doi.org/10.1016/S0140-6736(12)61769-3.PubMedCrossRefGoogle Scholar
  111. 111.
    Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89(11):1117–26.  https://doi.org/10.1212/WNL.0000000000004354.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Arnold DL, Fisher E, Brinar VV, et al. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS. Neurology. 2016;87(14):1464–72.  https://doi.org/10.1212/WNL.0000000000003169.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Button T, Altmann D, Tozer D, et al. Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Mult Scler. 2013;19(2):241–4.  https://doi.org/10.1177/1352458512444915.PubMedCrossRefGoogle Scholar
  114. 114.
    Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89(11):1107–16.  https://doi.org/10.1212/WNL.0000000000004313.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133(Pt 8):2232–47.  https://doi.org/10.1093/brain/awq176.PubMedCrossRefGoogle Scholar
  116. 116.
    Dubuisson N, Baker D, Kang AS, et al. Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology. 2018;154(2):253–60.  https://doi.org/10.1111/imm.12879.PubMedCrossRefGoogle Scholar
  117. 117.
    Somerfield J, Hill-Cawthorne GA, Lin A, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol. 2010;185(1):763–8.  https://doi.org/10.4049/jimmunol.1000422.PubMedCrossRefGoogle Scholar
  118. 118.
    Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996;98(12):2819–26.  https://doi.org/10.1172/JCI119110.PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Wing MG, Waldmann H, Isaacs J, et al. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype. Ther Immunol. 1995;2(4):183–90.PubMedGoogle Scholar
  120. 120.
    Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 1996;119(Pt 1):225–37.PubMedCrossRefGoogle Scholar
  121. 121.
    Blasco MR, Ramos A, Malo CG, et al. Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis. J Neurol. 2017;264(1):168–9.  https://doi.org/10.1007/s00415-016-8306-x.PubMedCrossRefGoogle Scholar
  122. 122.
    Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):298–304.  https://doi.org/10.1136/jnnp-2011-300826.PubMedCrossRefGoogle Scholar
  123. 123.
    Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691–5.  https://doi.org/10.1016/S0140-6736(99)02429-0.PubMedCrossRefGoogle Scholar
  124. 124.
    Azzopardi L, Thompson SA, Harding KE, et al. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(7):795–8.  https://doi.org/10.1136/jnnp-2013-307042.PubMedCrossRefGoogle Scholar
  125. 125.
    Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119(7):2052–61.  https://doi.org/10.1172/JCI37878.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Thompson SA, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30(1):99–105.  https://doi.org/10.1007/s10875-009-9327-3.PubMedCrossRefGoogle Scholar
  127. 127.
    Kousin-Ezewu O, Azzopardi L, Parker RA, et al. Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology. 2014;82(24):2158–64.  https://doi.org/10.1212/WNL.0000000000000520.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Jones JL, Thompson SA, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A. 2013;110(50):20200–5.  https://doi.org/10.1073/pnas.1313654110.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573–9.  https://doi.org/10.1212/WNL.0b013e318228bec5.PubMedCrossRefGoogle Scholar
  130. 130.
    Devonshire V, Phillips R, Wass H, et al. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. 2018;265(11):2494–505.  https://doi.org/10.1007/s00415-018-8822-y.CrossRefGoogle Scholar
  131. 131.
    EMA. Lemtrada (alemtuzumab): summary of product characteristics. European Medicines Agency. 2013. https://www.ema.europa.eu/documents/product-information/lemtrada-epar-product-information_en.pdf. Accessed 3 Jan 2018..
  132. 132.
    FDA. Lemtrada (alemtuzumab): highlights of prescribing information. Food and Drug Administration. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf. Accessed 03 Jan 2018.
  133. 133.
    Ibitoye R, Wilkins A. Thyroid papillary carcinoma after alemtuzumab therapy for MS. J Neurol. 2014;261(9):1828–9.  https://doi.org/10.1007/s00415-014-7453-1.PubMedCrossRefGoogle Scholar
  134. 134.
    Sprangers B, Decoo D, Dive D et al. Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus. Acta Neurol Belg. 2017.  https://doi.org/10.1007/s13760-017-0864-x.
  135. 135.
    Ruck T, Pfeuffer P, Schulte-Mecklenbeck A, et al. Vitiligo after alemtuzumab treatment: secondary autoimmunity is not all about B cells. Neurology. 2017;91(24):1–5.  https://doi.org/10.1212/WNL.0000000000006648.CrossRefGoogle Scholar
  136. 136.
    Zimmermann J, Buhl T, Müller M. Alopecia universalis following alemtuzumab treatment in multiple sclerosis: a barely recognized manifestation of secondary autoimmunity-report of a case and review of the literature. Front Neurol. 2017;8:569.  https://doi.org/10.3389/fneur.2017.00569.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    McCarthy CL, Tuohy O, Compston DA, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81(10):872–6.  https://doi.org/10.1212/WNL.0b013e3182a35215.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Holmoy T, von der Lippe H, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab—a case for better preventive strategies. BMC Neurol. 2017;17(1):65.  https://doi.org/10.1186/s12883-017-0848-8.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Rau D, Lang M, Harth A, et al. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis—report of two cases. Int J Mol Sci. 2015;16(7):14669–76.  https://doi.org/10.3390/ijms160714669.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Sheikh-Taha M, Corman LC. Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis. Mult Scler. 2017;23(6):872–4.  https://doi.org/10.1177/1352458517694431.PubMedCrossRefGoogle Scholar
  141. 141.
    Yann K, Jackson F, Sharaf N, et al. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis. Mult Scler Relat Disord. 2017;14:1–3.  https://doi.org/10.1016/j.msard.2017.03.001.PubMedCrossRefGoogle Scholar
  142. 142.
    Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis—success from bench to bedside. Nature Reviews Neurology. 2018.  https://doi.org/10.1038/s41582-018-0082-z.
  143. 143.
    Croteau D, Flowers C, Kulick CG, et al. Acute acalculous cholecystitis: a new safety risk for patients with MS treated with alemtuzumab. Neurology. 2018;90(18):e1548–52.  https://doi.org/10.1212/WNL.0000000000005422.PubMedCrossRefGoogle Scholar
  144. 144.
    Lapucci C, Gualandi F, Mikulska M, et al. Serum sickness (like reaction) in a patient treated with alemtuzumab for multiple sclerosis: a case report. Mult Scler Relat Disord. 2018;26:52–4.  https://doi.org/10.1016/j.msard.2018.09.006.PubMedCrossRefGoogle Scholar
  145. 145.
    Saarela M, Senthil K, Jones J, et al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018;90(18):849–51.  https://doi.org/10.1212/WNL.0000000000005420.PubMedCrossRefGoogle Scholar
  146. 146.
    Haghikia A, Dendrou CA, Schneider R, et al. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol. 2017;16(2):104–6.  https://doi.org/10.1016/S1474-4422(16)30382-9.PubMedCrossRefGoogle Scholar
  147. 147.
    Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol. 2013;9(7):394–404.  https://doi.org/10.1038/nrneurol.2013.95.PubMedCrossRefGoogle Scholar
  148. 148.
    Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373(15):1418–28.  https://doi.org/10.1056/NEJMoa1501481.PubMedCrossRefGoogle Scholar
  149. 149.
    Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006;103(15):5941–6.  https://doi.org/10.1073/pnas.0601335103.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9884):2167–75.  https://doi.org/10.1016/S0140-6736(12)62190-4.PubMedCrossRefGoogle Scholar
  151. 151.
    Krueger JG, Kircik L, Hougeir F, et al. Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. Advances In Therapy. 2016;33(7):1231–45.  https://doi.org/10.1007/s12325-016-0353-2.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. CNS Drugs. 2018;32(3):269–87.  https://doi.org/10.1007/s40263-018-0488-6.PubMedCrossRefGoogle Scholar
  153. 153.
    Giovannoni G, Kappos L, Gold R, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies. Mult Scler Relat Disord. 2016;9:36–46.  https://doi.org/10.1016/j.msard.2016.05.010.PubMedCrossRefGoogle Scholar
  154. 154.
    Luessi F, Engel S, Spreer A, et al. GFAPα IgG-associated encephalitis upon daclizumab treatment of MS. Neurol Neuroimmunol Neuroinflamm. 2018;5(5):e481.  https://doi.org/10.1212/NXI.0000000000000481.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci. 2009;1174:99–106.  https://doi.org/10.1111/j.1749-6632.2009.04939.x.PubMedCrossRefGoogle Scholar
  156. 156.
    Hauser SL, Belachew S, Kappos L. Ocrelizumab in primary progressive and relapsing multiple sclerosis. N Engl J Med. 2017;376(17):1694.  https://doi.org/10.1056/NEJMc1702076.PubMedCrossRefGoogle Scholar
  157. 157.
    Schutgens RE. Rituximab-induced serum sickness. Br J Haematol. 2006;135(2):147.  https://doi.org/10.1111/j.1365-2141.2006.06214.x.PubMedCrossRefGoogle Scholar
  158. 158.
    EMA. Ocrevus (ocrelizumab): summary of product characteristics. European Medicines Agency. 2018. https://www.ema.europa.eu/documents/product-information/ocrevus-epar-product-information_en.pdf. Accessed 3 Dec 2018.
  159. 159.
    Dunn N, Juto A, Ryner M, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018;24(9):1224–33.  https://doi.org/10.1177/1352458517720044.PubMedCrossRefGoogle Scholar
  160. 160.
    Kadish R, Robertson D, Sweeney M. Fatal leukoencephalopathy in a patient with multiple sclerosis following treatment with ocrelizumab. Neurology. 2018;90(15 supplement):5.353.Google Scholar
  161. 161.
    Tallantyre EC, Whittam DH, Jolles S et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018.  https://doi.org/10.1007/s00415-018-8812-0.
  162. 162.
    Makatsori M, Kiani-Alikhan S, Manson AL, et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014;107(10):821–8.  https://doi.org/10.1093/qjmed/hcu094.PubMedCrossRefGoogle Scholar
  163. 163.
    Christou EAA, Giardino G, Worth A, et al. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab. Int Rev Immunol. 2017;36(6):352–9.  https://doi.org/10.1080/08830185.2017.1346092.PubMedCrossRefGoogle Scholar
  164. 164.
    Kado R, Sanders G, McCune WJ. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy. Curr Opin Rheumatol. 2017;29(3):228–33.  https://doi.org/10.1097/BOR.0000000000000377.PubMedCrossRefGoogle Scholar
  165. 165.
    Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long? J Allergy Clin Immunol. 2015;136(5):1407–9.  https://doi.org/10.1016/j.jaci.2015.06.035.PubMedCrossRefGoogle Scholar
  166. 166.
    Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–39.  https://doi.org/10.1016/S0140-6736(12)61768-1.PubMedCrossRefGoogle Scholar
  167. 167.
    Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open. 2014;4(1):e004073.  https://doi.org/10.1136/bmjopen-2013-004073.PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    McCabe C, Chilcott J, Claxton K, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ. 2010;340:c1786.  https://doi.org/10.1136/bmj.c1786.PubMedCrossRefGoogle Scholar
  169. 169.
    Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72(3):315–8.  https://doi.org/10.1136/annrheumdis-2012-202941.PubMedCrossRefGoogle Scholar
  170. 170.
    Mahe J, Meurette A, Moreau A, et al. Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis. Drug Des Devel Ther. 2013;7:723–8.  https://doi.org/10.2147/DDDT.S42138.PubMedPubMedCentralCrossRefGoogle Scholar
  171. 171.
    Larochelle C, Grand’maison F, Bernier GP, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon beta. Mult Scler. 2014;20(13):1783–7.  https://doi.org/10.1177/1352458514523692.PubMedCrossRefGoogle Scholar
  172. 172.
    Jaber A, Driebergen R, Giovannoni G, et al. The Rebif new formulation story: it’s not trials and error. Drugs R D. 2007;8(6):335–48.PubMedCrossRefGoogle Scholar
  173. 173.
    Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther. 2007;29(6):1128–45.  https://doi.org/10.1016/j.clinthera.2007.06.002.PubMedCrossRefGoogle Scholar
  174. 174.
    Product information for AusPAR Rebif, interferon beta-1a. Merck Serono Australia. 2013. https://www.tga.gov.au/sites/default/files/auspar-interferon-beta-1a-131010-pi.docx. Accessed 8 Jan 2019.
  175. 175.
    Kelly CJ, Mir FA. Economics of biological therapies. BMJ. 2009;339:b3276.  https://doi.org/10.1136/bmj.b3276.PubMedCrossRefGoogle Scholar
  176. 176.
    Sarpatwari A, Avorn J, Kesselheim AS. Progress and hurdles for follow-on biologics. N Engl J Med. 2015;372(25):2380–2.  https://doi.org/10.1056/NEJMp1504672.PubMedCrossRefGoogle Scholar
  177. 177.
    Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol. 2017;13:503.  https://doi.org/10.1038/nrrheum.2017.81.PubMedCrossRefGoogle Scholar
  178. 178.
    Elkayam O, Pavelka K. Biologic registries in rheumatology: lessons learned and expectations for the future. Autoimmun Rev. 2012;12(2):329–36.  https://doi.org/10.1016/j.autrev.2012.05.009.
  179. 179.
    Zavada J, Lunt M, Davies R, et al. The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Ann Rheum Dis. 2014;73(1):252–5.  https://doi.org/10.1136/annrheumdis-2012-203102.PubMedCrossRefGoogle Scholar
  180. 180.
    Dennison EM, Packham J, Hyrich K. The BSRBR-RA at 15 years. Rheumatology. 2016;55(12):2093–5.  https://doi.org/10.1093/rheumatology/kew053.PubMedCrossRefGoogle Scholar
  181. 181.
    Klein K, Stolk P. Challenges and opportunities for the traceability of (biological) medicinal products. Drug Saf. 2018;41(10):911–8.  https://doi.org/10.1007/s40264-018-0678-7.PubMedPubMedCentralCrossRefGoogle Scholar
  182. 182.
    Vermeer NS, Spierings I, Mantel-Teeuwisse AK, et al. Traceability of biologicals: present challenges in pharmacovigilance. Expert Opin Drug Saf. 2015;14(1):63–72.  https://doi.org/10.1517/14740338.2015.972362.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Anne Rowling ClinicUniversity of EdinburghEdinburghUK
  2. 2.MRC Institute of Genetics and Molecular MedicineUniversity of EdinburghEdinburghUK

Personalised recommendations